Bengaluru, June 26, 2025: Medtronic, a global leader in medical technology, has announced the launch of the Micra™ AV2 and VR2, the world’s smallest leadless pacemakers, in India. These are designed to last longer, work better, and make life easier for patients with slow heart rhythms.
The Micra™ AV2 and VR2 are the latest innovations in the Medtronic Micra leadless pacemaker family. They do not have leads or require a chest incision, which helps avoid potential complications, like infections, that can happen with traditional pacemakers with leads. The Micra AV2 also has smart technology that adjusts to each person’s heartbeat, helping the heart stay in sync even when the person is moving around.
These new pacemakers are enhanced with extended battery longevity and streamlined implant procedures. They last longer with a median projected battery lifespan of 15.6 years for the Micra AV2 and 16.7 years for the Micra VR2, over 80% of patients will only need one for their whole life. They are also compatible with smartphone-enabled remote monitoring, which can help with care.
Chandrashekhar Jaiman, Director Cardiovascular at Medtronic India commented, “At Medtronic, our mission is to alleviate pain, restore health, and extend life. With the launch of the Micra AV2 and VR2 in India, we are proud to advance that mission by redefining what’s possible in cardiac care. These next-generation leadless pacemakers represent a significant leap forward—combining miniaturization with intelligent pacing technology to deliver a superior experience for both patients and clinicians. This innovation is especially meaningful in India, where the growing burden of cardiovascular disease calls for scalable, accessible, and clinically advanced solutions.”
Real-world data from global studies show that the Micra leadless pacemakers significantly reduce major complications by as much as 53% compared to traditional pacemakers. These leadless devices can help patients to recover from the procedure with minimal signs of a visible implant. With Micra AV2 and VR2, we are not only advancing the science of cardiac care but also reaffirming our commitment to engineering innovative, life-enhancing solutions for patients in India.